open access

Vol 12, No 4 (2017)
Case Reports
Published online: 2017-09-19
Get Citation

Effective levosimendan therapy in patient with exacerbation of chronic heart failure with reduced left ventricular ejection fraction

Kamil Janikowski, Małgorzata Lelonek
DOI: 10.5603/FC.2017.0070
·
Folia Cardiologica 2017;12(4):378-385.

open access

Vol 12, No 4 (2017)
Case Reports
Published online: 2017-09-19

Abstract

A 62-year-old man was admitted due to exacerbation of chronic heart failure symptoms to IV New York Heart Association class. Despite the standard pharmacotherapy of acute heart failure, the patient developed symptoms of organ hypoperfusion, followed by oliguria and anuria. The patient was qualified for levosimendan treatment, resulting in stabilization of his clinical status in subsequent days. The study presents the current knowledge of levosimendan use in acute heart failure.

Abstract

A 62-year-old man was admitted due to exacerbation of chronic heart failure symptoms to IV New York Heart Association class. Despite the standard pharmacotherapy of acute heart failure, the patient developed symptoms of organ hypoperfusion, followed by oliguria and anuria. The patient was qualified for levosimendan treatment, resulting in stabilization of his clinical status in subsequent days. The study presents the current knowledge of levosimendan use in acute heart failure.

Get Citation

Keywords

acute heart failure, pharmacotherapy, levosimendan

About this article
Title

Effective levosimendan therapy in patient with exacerbation of chronic heart failure with reduced left ventricular ejection fraction

Journal

Folia Cardiologica

Issue

Vol 12, No 4 (2017)

Pages

378-385

Published online

2017-09-19

DOI

10.5603/FC.2017.0070

Bibliographic record

Folia Cardiologica 2017;12(4):378-385.

Keywords

acute heart failure
pharmacotherapy
levosimendan

Authors

Kamil Janikowski
Małgorzata Lelonek

References (25)
  1. Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
  2. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009; 53(7): 557–573.
  3. Solomon SD, Dobson J, Pocock S, et al. Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007; 116(13): 1482–1487.
  4. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006; 27(22): 2725–2736.
  5. Landoni G, Biondi-Zoccai G, Greco M. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012; 40(2): 634–646.
  6. Rozentryt P. Zastój narządowy w niewydolności serca. Terapia. 2016; 9(2).
  7. SIMDAX® monografia produktu. Orion Pharma 2015.
  8. Follath F, Cleland JGF, Just H, et al. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002; 360(9328): 196–202.
  9. Moiseyev VS, Põder P, Andrejevs N, et al. RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002; 23(18): 1422–1432.
  10. Follath F, Yilmaz MB, Delgado JF, et al. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med. 2011; 37(4): 619–626.
  11. Pollesello P, Parissis J, Kivikko M, et al. Levosimendan meta-analyses: is there a pattern in the effect on mortality? Int J Cardiol. 2016; 209: 77–83.
  12. Cleland JGF, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail. 2004; 6(4): 501–508.
  13. Cleland JGF, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006; 8(1): 105–110.
  14. Ribeiro RA, Rohde LE, Polanczyk CA. Levosimendan in acute decompensated heart failure: systematic review and meta-analysis. Arq Bras Cardiol. 2010; 95(2): 230–237.
  15. Delaney A, Bradford C, McCaffrey J, et al. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. Int J Cardiol. 2010; 138(3): 281–289.
  16. Gong B, Li Z, Yat Wong PC. Levosimendan treatment for heart failure: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2015; 29(6): 1415–1425.
  17. Fedele F, D'Ambrosi A, Bruno N, et al. Cost-effectiveness of levosimendan in patients with acute heart failure. J Cardiovasc Pharmacol. 2011; 58(4): 363–366.
  18. Fedele F, Karason K, Matskeplishvili S. Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan. Eur Heart J Suppl. 2017; 19(Suppl C): C22–C28.
  19. Bragadottir G, Redfors B, Ricksten SE. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med. 2013; 41(10): 2328–2335.
  20. Farmakis D, Alvarez J, Gal TB, et al. Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. Int J Cardiol. 2016; 222: 303–312.
  21. Nikolaou M, Parissis J, Yilmaz MB, et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J. 2013; 34(10): 742–749.
  22. Simdax® — Charakterystyka Produktu Leczniczego.
  23. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused 4pdate of the 2013 ACCF/AHA guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017 [Epub ahead of print].
  24. Delgado JF, Oliva F, Reinecke A. The inodilator levosimendan in repetitive doses in the treatment of advanced heart failure. Eur Heart J Suppl. 2017; 19(Suppl C): C8–C14.
  25. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003; 107(1): 81–86.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl